Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: Outcomes from CATIE-AD

American Journal of Psychiatry

Volumn 168, Issue 8, 2011, Pages 831-839

  Vigen, Cheryl L P ^{a,b,c,d,e,f,g,h,i}   Mack, Wendy J ^{a,b,c,d,e,f,g,h,i}   Keefe, Richard S E ^{a,b,c,d,e,f,g,h,i}   Sano, Mary ^{a,b,c,d,e,f,g,h,i}   Sultzer, David L ^{a,b,c,d,e,f,g,h,i}   Stroup, T Scott ^{a,b,c,d,e,f,g,h,i}   Dagerman, Karen S ^{a,b,c,d,e,f,g,h,i}   Hsiao, John K ^{a,b,c,d,e,f,g,h,i}   Lebowitz, Barry D ^{a,b,c,d,e,f,g,h,i}   Lyketsos, Constantine G ^{a,b,c,d,e,f,g,h,i}   Tariot, Pierre N ^{a,b,c,d,e,f,g,h,i}   Zheng, Ling ^{a,b,c,d,e,f,g,h,i}   Schneider, Lon S ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Columbia University Medical School ^*  (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f BANNER HEALTH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

ADULT; AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGY; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PATIENT DROPOUTS; RISPERIDONE;

EID: 80052431861     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.08121844     Document Type: Article

References (32)

1. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., Breitner J.C.S.: Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708-714 (Pubitemid 30249648)
2. Ropacki S.A., Jeste D.V.: Epidemiology of and risk factors for psychosis of Alzheimer's disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005; 162:2022-2030 (Pubitemid 41598255)
3. Lopez O.L., Becker J.T., Sweet R.A., Klunk W., Kaufer D.I., Saxton J., Habeych M., DeKosky S.T.: Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2003; 15:346-353 (Pubitemid 36999378)
4. Craig D., Mirakhur A., Hart D.J., McIlroy S.P., Passmore A.P.: A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 2005; 13:460-468
5. Schulz R., O'Brien A.T., Bookwala J., Fleissner K.: Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995; 35:771-791
6. Magni E., Binetti G., Bianchetti A., Trabucchi M.: Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 1996; 9:123-126 (Pubitemid 26319348)
7. Stern Y., Tang M.X., Albert M.S., Brandt J., Jacobs D.M., Bell K., Marder K., Sano M., Devanand D., Albert S.M., Bylsma F., Tsai W.Y.: Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 227:806-812 (Pubitemid 27111316)
8. Schneider L.S., Dagerman K., Insel P.S.: Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
9. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A.: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A Review and meta-analysis. Schizophr Bull 1999; 25:201-222 (Pubitemid 29272501)
10. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H.: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8:457-472 (Pubitemid 41002500)
11. Harvey P.D., Keefe R.S.E.: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176-184 (Pubitemid 32116511)
12. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G.: Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect? Arch Gen Psychiatry 2007; 64:1115-1122 (Pubitemid 47529336)
13. Ballard C., Margallo-Lana M., Juszczak E., Douglas S., Swann A., Thomas A., O'Brien J., Everratt A., Sadler S., Maddison C., Lee L., Bannister C., Elvish R., Jacoby R.: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ 2005; 330:874-877 (Pubitemid 40545686)
14. Folstein M.F., Folstein S.E., McHugh P.R.: "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
15. Kennedy J., Deberdt W., Siegal A., Micca J., Degenhardt E., Ahl J., Meyers A., Kaiser C., Baker R.W.: Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int J Geriatr Psychiatry 2005; 20:1020-1027 (Pubitemid 41723572)
16. Schneider L.S., Ismail M.S., Dagerman K., Davis S., Olin J., McManus D., Pfeiffer E., Ryan J.M., Sultzer D.L., Tariot P.N.: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull 2003; 29:57-72 (Pubitemid 36871057)
17. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., Lebowitz B.D., Lyketsos C.G., Ryan J.M., Stroup T.S., Sultzer D.L., Weintraub D., Lieberman J.A.; CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538 (Pubitemid 44547805)
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M.: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944 (Pubitemid 14076461)
19. Overall J.E., Gorham D.R.: The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 24:97-99
20. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J.: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314 (Pubitemid 24382728)
21. Rosen W.G., Mohs R.C., Davis K.L.: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
22. Mohs R.C., Knopman D., Petersen R.C., Ferris S.H., Ernesto C., Grundman M., Sano M., Bieliauskas L., Geldmacher D., Clark C., Thal L.J.: Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope (Alzheimer's Disease Cooperative Study). Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S13-S21
23. Benton A.L.: Development of a multilingual aphasia battery: Progress and problems. J Neurol Sci 1969; 9:39-48
24. Doody R.S., Vacca J.L., Massman P.J., Liao T.Y.: The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Arch Neurol 1999; 56:1133-1137 (Pubitemid 29426801)
25. Amieva H., Lafont S., Auriacombe S., Rainville C., Orgogozo J.M., Dartigues J.F., Fabrigoule C.: Analysis of error types in the Trail Making Test evidences an inhibitory deficit in dementia of the Alzheimer type. J Clin Exp Neuropsychol 1998; 20:280-285 (Pubitemid 28451707)
26. Keefe R.S., Roitman S.E., Harvey P.D., Blum C.S., DuPre R.L., Prieto D.M., Davidson M., Davis K.L.: A pen-and-paper human analogue of a monkey prefrontal cortex activation task: Spatial working memory in patients with schizophrenia. Schizophr Res 1995; 17:25-33
27. Beller S.A., Overall J.E.: The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research, II: Representative profile patterns. J Gerontol 1984; 39:194-200 (Pubitemid 14156165)
28. Birks J.: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1:CD005593
29. Thomas R.G., Berg J.D., Sano M., Thal L.: Analysis of longitudinal data in an Alzheimer's disease clinical trial. Stat Med 2000; 19:1433-1440 (Pubitemid 30346236)
30. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A.; CATIE Investigators, Neurocognitive Working Group: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64:633-647 (Pubitemid 46878665)
31. Rocca P., Marino F., Montemagni C., Perrone D., Bogetto F.: Risperidone, olanzapine, and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: Preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci 2007; 61:622-629 (Pubitemid 350233486)
32. Sultzer D.L., Davis S.M., Tariot P.N., Dagerman K.S., Lebowitz B.D., Lyketsos C.G., Rosenheck R.A., Hsiao J.K., Lieberman J.A., Schneider L.S.; CATIE-AD Study Group: Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165:844-854 (Pubitemid 351948716)